BJH - volume 7, issue Abstract Book BHS, january 2016
E. Van Valckenborgh PhD, K. De Veirman , H. De Raeve MD, PhD, dr. K. Maes , E. De Bruyne , E. Menu , K. Vanderkerken PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
S. Vander Meeren , B. Heyrman MD, W. Renmans , K. Jochmans MD, PhD, M. Bakkus PhD, H. De Raeve MD, PhD, R. Schots MD, PhD, M. De Waele
BJH - 2013, issue BHS Abstractbook, january 2013
C. Caron , A. De Becker MD, K. Fostier MD, M. De Waele , H. De Raeve MD, PhD, R. Schots MD, PhD, F. Trullemans
BJH - volume 3, issue 3, september 2012
E. Del Biondo MD, H. De Raeve MD, PhD, G. Huysmans MD, K. Hendrickx MD, E. Wouters MD, P. Vandenberghe MD, PhD, P. Meeus MD
The coincidence of a Janus Kinase 2 (JAK2) V617F positive myeloproliferative neoplasm (MPN) and a BCR-ABL1 positive chronic myeloid leukaemia (CML) is rare. We present a patient whose bone marrow and peripheral blood showed typical features of essential thrombocytemia (ET). However, the normalisation of the white blood cell (WBC) count after therapy with imatinib for a gastrointestinal stromal tumour (GIST) suggests that an underlying CML was masked, as witnessed by the very low levels of BCR-ABL1 at the haematological diagnosis. The question remains if this is a case of two separate myeloid malignancies or a secondary event (BCR-ABL1 fusion) in a primary JAK2 V617F + ET.
(BELG J HEMATOL 2012:3:105–107)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
